Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease

https://doi.org/10.20996/1819-6446-2019-15-4-530-537

Full Text:

Abstract

The purpose of this review is to examine the possibilities and prospects for the use of direct oral anticoagulants for the prevention of thromboembolic complications in patients with atrial fibrillation and chronic kidney disease. Chronic kidney disease is an independent risk factor for cardiovascular complications. Atrial fibrillation is associated with a higher risk of developing chronic kidney disease and more rapid progression of existing renal pathology. The presence of chronic kidney disease in atrial fibrillation on the one hand leads to an increased risk of thromboembolism, and on the other to an increased risk of bleeding when using anticoagulants. The standard for the prevention of thromboembolic complications in atrial fibrillation, including those with concomitant renal pathology, was considered warfarin for many years. However, modern studies have shown that the use of warfarin may enhance vascular calcification in patients with chronic kidney disease, which in turn may lead to an increased risk of ischemic strokes.

Analyzing clinical recommendations, randomized studies, meta-analyzes and a systematic review on the use of anticoagulants in patients with atrial fibrillation and renal pathology, revealed the advantage of using direct oral anticoagulants over warfarin at stage 1-3 of chronic kidney disease. Data on the use of direct oral anticoagulants with a more pronounced renal dysfunction and in patients on dialysis is limited due to the lack of a sufficient number of large randomized studies. Due to the presence of renal clearance in all oral anticoagulants, their pharmacokinetics changes to some extent with a decrease in the glomerular filtration rate, which requires dose adjustment of drugs depending on creatinine clearance. Therefore, the use of anticoagulants for the prevention of thromboembolic complications during atrial fibrillation requires special attention in patients with chronic kidney disease.

About the Authors

V. I. Petrov
Volgograd State Medical University
Russian Federation

Vladimir I. Petrov – MD, PhD, Professor, Academician of the Russian Academy of Sciences, Head of Chair of Clinical Pharmacology, Intensive Care and Resuscitation with the Course of Clinical Pharmacology and Clinical Allergology Faculty of Advanced Training of the Doctors

Pavshikh Bortsov pl. 1, Volgograd, 400131 Russia



O. V. Shatalova
Volgograd State Medical University
Russian Federation

Olga V. Shatalova – MD, PhD, Associate Professor, Chair of Clinical Pharmacology, Intensive Care and Resuscitation with the Course of Clinical Pharmacology and Clinical Allergology Faculty of Advanced Training of the Doctors

Pavshikh Bortsov pl. 1, Volgograd, 400131 Russia



A. S. Gerasimenko
Volgograd State Medical University
Russian Federation

Anastasia S. Gerasimenko ‒ Postgraduate Student, Chair of Clinical Pharmacology, Intensive Care and Resuscitation with the Course of Clinical Pharmacology and Clinical Allergology Faculty of Advanced Training of the Doctors

Pavshikh Bortsov pl. 1, Volgograd, 400131 Russia



V. S. Gorbatenko
Volgograd State Medical University
Russian Federation

Vladislav S. Gorbatenko ‒ MD, PhD, Assistant, Chair of Clinical Pharmacology, Intensive Care and Resuscitation with the Course of Clinical Pharmacology and Clinical Allergology Faculty of Advanced Training of the Doctors

Pavshikh Bortsov pl. 1, Volgograd, 400131 Russia



References

1. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/europace/euw295.

2. Zoni-Berisso M., Lercari F., Carazza T., Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-20. DOI:10.2147/CLEP.S47385.

3. Soliman E.Z., Prineas R.J., Go A.S., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159:1102-07. DOI:10.1016/j.ahj.2010.03.027.

4. Hart R.G., Eikelboom J.W., Brimble K.S., et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29:71-8. DOI:10.1016/j.cjca.2013.04.005.

5. Reinecke H., Brand E., Mesters R., et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20:705-12. DOI:10.1681/ASN.2007111207.

6. Watanabe H., Watanabe T., Sasaki S. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629-36. DOI:10.1016/j.ahj.2009.06.031.

7. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946-53. DOI:10.1161/CIRCULATIONAHA.111.020982.

8. Antza C., Doundoulakis I., Akrivos E., et al. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. Scand Cardiovasc J. 2019;21:1-22. DOI:10.1080/14017431. 2019.1594353.

9. Albertsen I.E., Rasmussen L.H., Overvad T.F., et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-analysis. Stroke. 2013;44:132936. DOI:10.1161/StrokeAHA.113.000883.

10. Shishkova V.N. Chronic kidney disease and cardiovascular diseases: focus on atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2015;11(2):196-201 (In Russ.). DOI:10.20996/1819-6446-2015-11-2-196-201.

11. De Vriese A.S., Caluwè R., Raggi P. The atrial fibrillation conundrum in dialysis patients. Am Heart J. 2016;174:111-9. DOI:10.1016/j.ahj.2016.01.010.

12. Chan K.E., Giugliano R.P., Patel M.R., et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;672888-99. DOI:10.1016/j.jacc.2016.02.082.

13. Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation. Eur Heart J. 2018;39:1330-93. DOI:10.1093/eurheartj/ehy136.

14. Steffel J., Giugliano R.P., Braunwald E., et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239-45. DOI:10.1093/eurheartj/ehv643.

15. Moiseev V.C., Mukhin N.A., Smirnov A.V., et al. Сardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;(8):7-37. (In Russ.) . DOI:10.15829/1560-4071-2014-8-7-37.

16. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron.1976;16:31-41.

17. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32. DOI:10.1056/NEJMoa0907845.

18. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-70.

19. Schwartz J.B. Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants. J Am Geriatr Soc. 2016;64(10):1996-2002. DOI:10.1111/jgs.14288.

20. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.

21. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.

22. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. DOI:10.1161/CIRCULATIONAHA.

23. Patel M.R., Mahaffey K.W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.

24. López-López J.A., Sterne J.A.C., Thom H.H.Z., et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:5058. DOI:10.1136/bmj.j5058.

25. Fox K.A.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. DOI:10.1093/eurheartj/ehr342.

26. Xarelto. Instructions for use of the drug for medical use. [cited by Jun 15, 2019]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a80355f3-299b-4ff2-ac032ba27235c453&t= (In Russ.) .

27. Granger C.B., Alexander J.H., McMurray J.J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NEJMoa1107039.

28. Alexander K.P., Brouwer M.A., Mulder H., et al. ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019;208:123-31. DOI:10.1016/j.ahj.2018.09.017.

29. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12. DOI:10.7326/0003-4819-150-9-200905050-00006.

30. Hohnloser S.H., Hijazi Z., Thomas L. et al. Efficacy of apixaban when compared with warfarin inrelation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-30. DOI:10.1093/eurheartj/ehs274.

31. Wang X., Tirucherai G., Marbury T.C. et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):62836. DOI:10.1002/jcph.628.

32. Eliquis. Instructions for use of the drug for medical use. [cited byJun 15, 2019]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=de6b807f-2bf4-4fb2-b0836b77e859f090&t= (In Russ.) .

33. Dolly A.P., Kenneth E. Truitt Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa Clinical Pharmacokinetics Clinical Pharmacokinetics. 2016;55(6):641. DOI:10.1007/s40262-015-0342-7.

34. Bohula E.A., Giugliano R.P., Ruff C.T., et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134:24-36. DOI:10.1161/CIRCULATIONAHA.116.022361.

35. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-94. DOI:10.1093/eurheartj/ehr342.

36. Hijazi Z., Hohnloser S.H., Andersson U., et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1:451-60. DOI:10.1001/jamacardio.2016.1170.

37. Fordyce C.B., Hellkamp A.S., Lokhnygina Y., et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016;134:37-47. DOI:10.1161/CIRCULATIONAHA.116.021890.

38. Kimachi M., Furukawa T.A., Kimachi K., et al. Direct oral anticoagulants versus warfarin for preventing stroke andsystemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11:CD011373. DOI:10.1002/14651858.CD011373.pub2.

39. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339-48. DOI:10.1016/j.jacc.2010.12.013.

40. Chan K.E., Edelman E.R., Wengeret J.B., et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972-9. DOI:10.1161/CIRCULATIONAHA.114.014113.

41. De Vriese A.S., Caluwé R., Bailleul E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015;66(1):91-8. DOI:10.1053/j.ajkd.2015.01.022.

42. Dias C., Moore K.T., Murphy J., et al. Pharmacokinetics, pharmacodynamics, and safety of singledose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43(4):229-36. DOI:10.1159/000445328.

43. Parasrampuria D.A., Marbury T., Matsushima N., et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015;113(4):719-27. DOI:10.1160/TH14-06-0547.

44. Wang X., Tirucherai G., Marbury T.C., et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5): 628-36. DOI:10.1002/jcph.628.


For citation:


Petrov V.I., Shatalova O.V., Gerasimenko A.S., Gorbatenko V.S. Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease. Rational Pharmacotherapy in Cardiology. 2019;15(4):530-537. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-4-530-537

Views: 76


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)